Esperion Therapeutics Statistics
Total Valuation
ESPR has a market cap or net worth of $352.69 million. The enterprise value is $476.94 million.
Important Dates
The next estimated earnings date is Tuesday, February 25, 2025, before market open.
| Earnings Date | Feb 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ESPR has 197.04 million shares outstanding. The number of shares has increased by 78.21% in one year.
| Current Share Class | 197.04M |
| Shares Outstanding | 197.04M |
| Shares Change (YoY) | +78.21% |
| Shares Change (QoQ) | +3.25% |
| Owned by Insiders (%) | 0.75% |
| Owned by Institutions (%) | 66.73% |
| Float | 195.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.01 |
| Forward PS | 1.33 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.61 |
| EV / EBITDA | 28.91 |
| EV / EBIT | 28.98 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.85
| Current Ratio | 1.85 |
| Quick Ratio | 1.28 |
| Debt / Equity | n/a |
| Debt / EBITDA | 15.57 |
| Debt / FCF | n/a |
| Interest Coverage | 0.28 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 3.84% |
| Return on Invested Capital (ROIC) | 101.42% |
| Return on Capital Employed (ROCE) | 11.10% |
| Revenue Per Employee | $1.23M |
| Profits Per Employee | -$361,546 |
| Employee Count | 240 |
| Asset Turnover | 1.10 |
| Inventory Turnover | 1.63 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.39% in the last 52 weeks. The beta is 1.03, so ESPR's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | -11.39% |
| 50-Day Moving Average | 2.42 |
| 200-Day Moving Average | 2.20 |
| Relative Strength Index (RSI) | 31.13 |
| Average Volume (20 Days) | 5,242,066 |
Short Selling Information
The latest short interest is 33.98 million, so 17.24% of the outstanding shares have been sold short.
| Short Interest | 33.98M |
| Short Previous Month | 32.35M |
| Short % of Shares Out | 17.24% |
| Short % of Float | 17.38% |
| Short Ratio (days to cover) | 7.21 |
Income Statement
In the last 12 months, ESPR had revenue of $295.45 million and -$86.77 million in losses. Loss per share was -$0.52.
| Revenue | 295.45M |
| Gross Profit | 188.03M |
| Operating Income | 16.46M |
| Pretax Income | -98.50M |
| Net Income | -86.77M |
| EBITDA | 16.50M |
| EBIT | 16.46M |
| Loss Per Share | -$0.52 |
Full Income StatementBalance Sheet
The company has $144.72 million in cash and $268.96 million in debt, giving a net cash position of -$124.25 million or -$0.63 per share.
| Cash & Cash Equivalents | 144.72M |
| Total Debt | 268.96M |
| Net Cash | -124.25M |
| Net Cash Per Share | -$0.63 |
| Equity (Book Value) | -370.21M |
| Book Value Per Share | -1.89 |
| Working Capital | 141.68M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$25.76 million and capital expenditures -$317,000, giving a free cash flow of -$26.08 million.
| Operating Cash Flow | -25.76M |
| Capital Expenditures | -317,000 |
| Free Cash Flow | -26.08M |
| FCF Per Share | -$0.13 |
Full Cash Flow StatementMargins
Gross margin is 63.64%, with operating and profit margins of 5.57% and -29.37%.
| Gross Margin | 63.64% |
| Operating Margin | 5.57% |
| Pretax Margin | -29.37% |
| Profit Margin | -29.37% |
| EBITDA Margin | 5.58% |
| EBIT Margin | 5.57% |
| FCF Margin | n/a |
Dividends & Yields
ESPR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -78.21% |
| Shareholder Yield | -78.21% |
| Earnings Yield | -24.60% |
| FCF Yield | -7.39% |
Analyst Forecast
The average price target for ESPR is $7.25, which is 305.03% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.25 |
| Price Target Difference | 305.03% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 46.28% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ESPR has an Altman Z-Score of -5.09 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.09 |
| Piotroski F-Score | 6 |